dimer

Oxytocin parallel dimer is a homo peptide dimer connected by a disulfide bridge.

Oxytocin antiparallel dimer is a disulfide-bridged homopeptide dimer.

Oxytocin Parallel Dimer TFA, a disulfide-bridged homopeptide dimer, exhibits both oxytocin and vasopressin-like activity while being less toxic than oxytocin [1] [2].

Vasopressin Dimer (parallel) TFA, a parallel dimer of Vasopressin, has the capability to activate four G protein-coupled receptors—namely, V1aR, V1bR, V2R, and OTR [1].

Vasopressin Dimer (anti-parallel) TFA, an anti-parallel dimer form of vasopressin, has the capability to activate four G protein-coupled receptors: V1aR, V1bR, V2R, and OTR [1].

Oxytocin antiparallel dimer TFA is a homo peptide dimer connected by a disulfide bridge, exhibiting activities similar to oxytocin and vasopressin but with reduced toxicity [1] [2].

High affinity caveolin-1 (CAV1) ligand (Kd = 23 nM); disrupts caveolin-1 oligomers. Exhibits selectivity for CAV1 over BSA, casein and HEWL.

DOTA-cyclo(RGDfK) is a and DOTA-like chelator peptide consisting of a dimer of the peptide cross-linker DOTA and the cyclic peptide RGDFK, which preferentially targets the αvβ3 integrin receptor expressed on tumor cell membranes, allowing for the preparation of radionuclide coupled compounds (RDCs) and their use in cancer diagnostics and therapy.

Mambalgin 1 TFA, a selective inhibitor of ASIC1a (with IC50 values of 192 nM for human ASIC1a and 72 nM for the ASIC1a/1b dimer), preferentially binds to the channel in its closed/inactive state. It demonstrates selectivity for ASIC1a over a range of other channels, including ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2, and Kv1.2. In vivo, Mambalgin 1 TFA effectively prolongs the latency of the withdrawal response in mouse tail-flick and paw-flick tests.

Albiglutide fragment (GLP-1 (7-36) analog) TFA represents a biologically active segment of Albiglutide, resistant to DPP-4 degradation due to its structure as a GLP-1 analog. It functions as a long-acting agonist of the GLP-1 receptor, derived from a fusion of a GLP-1 dimer with the human albumin gene. Clinically, this compound demonstrates a pronounced reduction in glycosylated hemoglobin (A1C) levels, rendering it a valuable therapeutic in type 2 diabetes (T2D) research [1] [2] [3] [4].

Amyloid-Forming peptide GNNQQNY, a biologically active heptapeptide derived from the N-terminal prion-determining domain of yeast Sup35, is instrumental in amyloid fibril formation. Its atomic oligomeric structure has been detailed, serving as an excellent model for investigating early-stage aggregation. The peptide can form three stable β-sheet structures: in-register parallel, off-register parallel, and anti-parallel. Notably, the in-register parallel dimer aligns closely with amyloid β-sheet architecture, relying on fewer interpeptide hydrogen bonds and emphasizing hydrophobic interactions, which enhances conformational entropy relative to the anti-parallel arrangement.

Selective ASIC1a inhibitor (IC50 values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Binds to closed/inactive channel. Selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Increases late

LH2 peptide is a pH-responsive, cell-penetrating peptide dimer with the amino acid sequence LHHLCHLLHHLCHLAG. It increases uptake in tumor cells in slightly acidic environments (such as the tumor microenvironment) through histidine residue protonation (pKa approximately 6). When conjugated with the anticancer agent paclitaxel to form PTX-LH2, it demonstrates superior tumor inhibition compared to paclitaxel alone in a subcutaneous breast tumor model. LH2 peptide holds promise as a delivery vector for cancer research.

QMT-CBT is a near-infrared aggregation-induced emission compound. Upon activation of caspase1 (Cas1), QMT-CBT undergoes a CBT-Cys click reaction, forming a cyclic dimer known as QMT-Dimer (the first aggregate), which further assembles into nanoparticles (the second aggregate). This process turns on the AIE signal, enhancing imaging for Alzheimer's disease (AD).

(123B9)2-L2-PTX is an EphA2 agonist peptide-drug conjugate (PDC). It consists of dimer 123B9 and Paclitaxel. This compound significantly reduces circulating tumor cells and inhibits lung metastasis in a breast cancer metastasis mouse model. (123B9)2-L2-PTX is applicable in cancer research, including studies on melanoma, ovarian cancer, and breast cancer.